Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Advertise with Us Top Online Brokers Become an Affiliate TipRanks News Wire

TOOLS

Top Smart Score Stocks

STOCKS

Research Tools

Most Visited Websites

Daily Feeds

Daily Analyst Ratings

Daily Insider Trading Tracker

Calendars

Economic Indicators

Economic Indicators Center

Inflation Rate

Unemployment Rate

Federal Funds Rate

Class Actions

Calculators

Dividend Calculator

Dividend Yield Calculator

Options Profit Calculator

Dollar Cost Averaging

Technical Analysis Screener

Dividend Center

Best Dividend Stocks

Popular

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

ImmunoPrecise Antibodies (IPA)

NASDAQ:IPA

IPA

ImmunoPrecise Antibodies

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding IPA?

Track your performance easily

Link Broker

ImmunoPrecise Antibodies (IPA) Income Statement

155 Followers

ImmunoPrecise Antibodies Income Statement

Last quarter (Q2 2025), ImmunoPrecise Antibodies's total revenue was C$6.13M, a decrease of -0.41% from the same quarter last year. In Q2, ImmunoPrecise Antibodies's net income was C$-2.55M. See ImmunoPrecise Antibodies’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Apr 24	Apr 23	Apr 22	Apr 21	Apr 20
Total Revenue	C$ 24.07M	C$ 24.52M	C$ 20.66M	C$ 19.36M	C$ 17.91M	C$ 14.06M
Cost of Revenue	C$ 11.97M	C$ 12.46M	C$ 9.10M	C$ 8.38M	C$ 6.37M	C$ 6.02M
Gross Profit	C$ 12.10M	C$ 12.05M	C$ 11.56M	C$ 10.98M	C$ 11.54M	C$ 8.03M
Operating Expense	C$ 26.60M	C$ 26.15M	C$ 37.51M	C$ 27.66M	C$ 15.71M	C$ 11.86M
Operating Income	C$ -14.51M	C$ -14.09M	C$ -25.94M	C$ -16.67M	C$ -4.18M	C$ -3.83M
Net Non Operating Interest Income Expense	C$ -610.00K	C$ 4.00K	C$ 92.00K	C$ -194.00K	C$ 581.00K	C$ 1.39M
Other Income Expense	C$ -200.00K	C$ -331.00K	C$ -332.00K	C$ 631.00K	C$ -1.24M	C$ -82.00K
Pretax Income	C$ -30.12M	C$ -28.70M	C$ -27.75M	C$ -15.85M	C$ -6.00M	C$ -5.29M
Tax Provision	C$ -2.58M	C$ -1.53M	C$ 1.19M	C$ 861.00K	C$ 1.34M	C$ -346.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -27.54M	C$ -27.18M	C$ -28.94M	C$ -16.71M	C$ -7.34M	C$ -4.95M
Basic EPS	C$ -1.03	C$ -1.06	C$ -1.07	C$ -0.85	C$ -0.45	C$ -1.75
Diluted EPS	C$ -1.03	C$ -1.06	C$ -1.07	C$ -0.85	C$ -0.45	C$ -1.75
Basic Average Shares	C$ 107.71M	C$ 25.64M	C$ 24.90M	C$ 19.69M	C$ 16.47M	C$ 2.73M
Diluted Average Shares	C$ 107.71M	C$ 25.64M	C$ 24.90M	C$ 19.69M	C$ 16.47M	C$ 2.73M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 38.58M	C$ 38.61M	-	C$ 36.04M	C$ -22.09M	C$ -17.88M
Net Income From Continuing And Discontinued Operation	C$ -27.54M	C$ -27.18M	C$ -28.94M	C$ -16.71M	C$ -7.34M	C$ -4.95M
Normalized Income	C$ -17.67M	C$ -15.20M	C$ -17.94M	C$ -11.76M	C$ -4.40M	C$ -4.58M
Interest Expense	-	-	-	-	-	-
EBIT	C$ -29.86M	C$ -28.70M	C$ -27.75M	C$ -15.76M	C$ -5.13M	C$ -3.86M
EBITDA	C$ -24.16M	C$ -22.97M	C$ -21.07M	C$ -11.99M	C$ -1.42M	C$ -449.00K

Currency in CAD

ImmunoPrecise Antibodies Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing